Your patient has a sudden high fever, "lead pipe" rigidity, perfuse sweating, some dysrhythmias and blood pressure that is fluctuating. Your patient has been taking a high potency first generation antipsychotic medication. What is this patient experiencing?

Management of patients on antidepressant therapy such as Selective serotonin reuptake inhibitors requires close monitoring for worsening depression and emergence of suicidal ideation, especially in young adults. Early in treatment, increased energy may precede improvement in mood, potentially elevating suicide risk in high-risk individuals. A patient with a concrete plan and history of prior attempts represents an acute psychiatric emergency. Safety becomes the immediate priority over medication adjustments or outpatient follow-up.

Rationale:
A. Changing the medication to another drug class may be considered later, but it does not address the immediate risk of self-harm. Antidepressant adjustments take time to show effect and do not provide rapid protection against suicide risk. The priority is ensuring patient safety rather than modifying pharmacologic therapy at this stage.

B. Discontinuing the medication immediately is not the priority intervention and may worsen withdrawal symptoms or depressive symptoms. Abrupt cessation of SSRIs can also lead to discontinuation syndrome, including agitation and mood instability. The immediate concern is stabilization and protection of the patient rather than sudden pharmacologic changes.

C. Requiring more frequent clinic visits may be appropriate for mild risk situations, but it is insufficient in the presence of an active suicide plan and prior attempts. Outpatient management does not provide the level of supervision needed to prevent imminent self-harm. The severity of risk exceeds what can be safely managed in a clinic setting.

D. Hospitalizing the patient for closer monitoring is the priority action due to the presence of a concrete suicide plan and a history of prior attempts. Inpatient care allows continuous observation, environmental safety control, and rapid psychiatric intervention. It ensures immediate protection while treatment adjustments and comprehensive risk management are initiated.

Methadone is a long-acting opioid agonist used in medication-assisted treatment for opioid use disorder. While effective in reducing cravings and withdrawal symptoms, it carries important cardiac risks due to its effect on cardiac ion channels. One of the most clinically significant adverse effects is QT interval prolongation, which can lead to life-threatening ventricular arrhythmias. Continuous cardiac monitoring and risk assessment are essential during long-term therapy.

Rationale:
A. AV block is not a primary or characteristic adverse effect of methadone therapy. Although severe cardiac conduction abnormalities may occur in extreme toxicity, methadone is specifically associated with ventricular repolarization abnormalities rather than atrioventricular nodal block. Therefore, AV block is not the key monitoring concern.

B. Prolonged QT interval is the most important cardiac adverse effect associated with Methadone. It occurs due to blockade of cardiac potassium channels, leading to delayed ventricular repolarization. This increases the risk of torsades de pointes, a potentially fatal ventricular arrhythmia. Monitoring ECG changes is essential during long-term therapy.

C. Prolonged PR interval reflects delayed atrioventricular conduction, which is not the typical effect seen with methadone use. Methadone primarily affects ventricular repolarization rather than atrioventricular conduction pathways. Therefore, PR interval prolongation is not a key expected finding.

D. An elevated QRS complex suggests intraventricular conduction delay or sodium channel blockade, which is not the primary electrophysiologic effect of methadone. While severe overdose may cause generalized cardiac toxicity, the hallmark and most clinically relevant change is QT prolongation rather than QRS widening.